Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.

No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.

Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

InvestingPro's Fair Value model identified (NASDAQ:SYRE) as significantly overvalued at $37.65, providing investors with a crucial warning signal. Nearly a year later, this analysis has proven ...

Clinical trials help researchers studying chronic conditions answer important questions about the diseases and their treatment options. However, uncertainty about what to expect and a lack of ...